|
Gene: ARHGEF11 |
Gene summary for ARHGEF11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARHGEF11 | Gene ID | 9826 |
Gene name | Rho guanine nucleotide exchange factor 11 | |
Gene Alias | GTRAP48 | |
Cytomap | 1q23.1 | |
Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | O15085 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9826 | ARHGEF11 | CCI_1 | Human | Cervix | CC | 2.19e-06 | 6.44e-01 | 0.528 |
9826 | ARHGEF11 | CCI_3 | Human | Cervix | CC | 1.82e-14 | 8.42e-01 | 0.516 |
9826 | ARHGEF11 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.20e-04 | -3.10e-01 | 0.0155 |
9826 | ARHGEF11 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.48e-04 | -2.26e-01 | 0.294 |
9826 | ARHGEF11 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.81e-05 | -2.88e-01 | 0.3005 |
9826 | ARHGEF11 | F007 | Human | Colorectum | FAP | 6.32e-03 | -3.68e-01 | 0.1176 |
9826 | ARHGEF11 | A015-C-203 | Human | Colorectum | FAP | 1.21e-22 | -3.83e-01 | -0.1294 |
9826 | ARHGEF11 | A015-C-204 | Human | Colorectum | FAP | 4.72e-09 | -3.31e-01 | -0.0228 |
9826 | ARHGEF11 | A014-C-040 | Human | Colorectum | FAP | 8.07e-03 | -3.42e-01 | -0.1184 |
9826 | ARHGEF11 | A002-C-201 | Human | Colorectum | FAP | 5.02e-11 | -3.03e-01 | 0.0324 |
9826 | ARHGEF11 | A001-C-119 | Human | Colorectum | FAP | 6.79e-06 | -4.28e-01 | -0.1557 |
9826 | ARHGEF11 | A001-C-108 | Human | Colorectum | FAP | 9.91e-15 | -3.10e-01 | -0.0272 |
9826 | ARHGEF11 | A002-C-205 | Human | Colorectum | FAP | 4.79e-19 | -4.55e-01 | -0.1236 |
9826 | ARHGEF11 | A015-C-005 | Human | Colorectum | FAP | 2.89e-02 | -1.43e-01 | -0.0336 |
9826 | ARHGEF11 | A015-C-006 | Human | Colorectum | FAP | 3.47e-11 | -3.47e-01 | -0.0994 |
9826 | ARHGEF11 | A015-C-106 | Human | Colorectum | FAP | 3.38e-09 | -2.26e-01 | -0.0511 |
9826 | ARHGEF11 | A002-C-114 | Human | Colorectum | FAP | 5.98e-16 | -4.25e-01 | -0.1561 |
9826 | ARHGEF11 | A015-C-104 | Human | Colorectum | FAP | 1.44e-22 | -3.76e-01 | -0.1899 |
9826 | ARHGEF11 | A001-C-014 | Human | Colorectum | FAP | 2.59e-13 | -3.18e-01 | 0.0135 |
9826 | ARHGEF11 | A002-C-016 | Human | Colorectum | FAP | 2.04e-18 | -3.41e-01 | 0.0521 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
GO:00160498 | Cervix | CC | cell growth | 92/2311 | 482/18723 | 1.16e-05 | 2.49e-04 | 92 |
GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
GO:00015588 | Cervix | CC | regulation of cell growth | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
GO:0007163 | Colorectum | AD | establishment or maintenance of cell polarity | 77/3918 | 218/18723 | 5.72e-07 | 2.08e-05 | 77 |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
GO:0030010 | Colorectum | AD | establishment of cell polarity | 50/3918 | 143/18723 | 6.90e-05 | 1.11e-03 | 50 |
GO:0007266 | Colorectum | AD | Rho protein signal transduction | 42/3918 | 137/18723 | 4.64e-03 | 3.16e-02 | 42 |
GO:00071632 | Colorectum | MSS | establishment or maintenance of cell polarity | 72/3467 | 218/18723 | 1.90e-07 | 8.30e-06 | 72 |
GO:00300102 | Colorectum | MSS | establishment of cell polarity | 47/3467 | 143/18723 | 2.74e-05 | 5.58e-04 | 47 |
GO:00160492 | Colorectum | MSS | cell growth | 123/3467 | 482/18723 | 7.15e-05 | 1.21e-03 | 123 |
GO:00072651 | Colorectum | MSS | Ras protein signal transduction | 91/3467 | 337/18723 | 7.20e-05 | 1.21e-03 | 91 |
GO:00510561 | Colorectum | MSS | regulation of small GTPase mediated signal transduction | 82/3467 | 302/18723 | 1.31e-04 | 1.99e-03 | 82 |
GO:00015582 | Colorectum | MSS | regulation of cell growth | 105/3467 | 414/18723 | 2.97e-04 | 3.90e-03 | 105 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0492812 | Cervix | CC | Parathyroid hormone synthesis, secretion and action | 27/1267 | 106/8465 | 3.12e-03 | 1.19e-02 | 7.03e-03 | 27 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0492813 | Cervix | CC | Parathyroid hormone synthesis, secretion and action | 27/1267 | 106/8465 | 3.12e-03 | 1.19e-02 | 7.03e-03 | 27 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa04928 | Colorectum | AD | Parathyroid hormone synthesis, secretion and action | 38/2092 | 106/8465 | 6.60e-03 | 2.77e-02 | 1.76e-02 | 38 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051631 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa049281 | Colorectum | AD | Parathyroid hormone synthesis, secretion and action | 38/2092 | 106/8465 | 6.60e-03 | 2.77e-02 | 1.76e-02 | 38 |
hsa051304 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051634 | Colorectum | MSS | Human cytomegalovirus infection | 74/1875 | 225/8465 | 1.12e-04 | 1.01e-03 | 6.19e-04 | 74 |
hsa049284 | Colorectum | MSS | Parathyroid hormone synthesis, secretion and action | 37/1875 | 106/8465 | 1.72e-03 | 9.13e-03 | 5.59e-03 | 37 |
hsa051305 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051635 | Colorectum | MSS | Human cytomegalovirus infection | 74/1875 | 225/8465 | 1.12e-04 | 1.01e-03 | 6.19e-04 | 74 |
hsa049285 | Colorectum | MSS | Parathyroid hormone synthesis, secretion and action | 37/1875 | 106/8465 | 1.72e-03 | 9.13e-03 | 5.59e-03 | 37 |
hsa051308 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa051636 | Colorectum | FAP | Human cytomegalovirus infection | 55/1404 | 225/8465 | 1.42e-03 | 7.67e-03 | 4.67e-03 | 55 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGEF11 | SNV | Missense_Mutation | c.2312N>T | p.Arg771Leu | p.R771L | O15085 | protein_coding | deleterious(0.01) | benign(0.289) | TCGA-CV-6941-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ARHGEF11 | SNV | Missense_Mutation | novel | c.4243G>A | p.Asp1415Asn | p.D1415N | O15085 | protein_coding | deleterious_low_confidence(0.03) | benign(0.006) | TCGA-CV-7410-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
ARHGEF11 | SNV | Missense_Mutation | rs766925017 | c.1013A>G | p.Tyr338Cys | p.Y338C | O15085 | protein_coding | tolerated(0.15) | benign(0.104) | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ARHGEF11 | SNV | Missense_Mutation | novel | c.3971N>T | p.Ser1324Phe | p.S1324F | O15085 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-D6-6516-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ARHGEF11 | SNV | Missense_Mutation | c.827N>T | p.Ser276Leu | p.S276L | O15085 | protein_coding | tolerated(0.66) | benign(0.007) | TCGA-G9-6499-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | SD | |
ARHGEF11 | insertion | Frame_Shift_Ins | novel | c.2169_2170insC | p.Ser724GlnfsTer17 | p.S724Qfs*17 | O15085 | protein_coding | TCGA-KK-A59V-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD | ||
ARHGEF11 | SNV | Missense_Mutation | c.1747N>T | p.Pro583Ser | p.P583S | O15085 | protein_coding | deleterious(0) | possibly_damaging(0.818) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
ARHGEF11 | SNV | Missense_Mutation | c.2312N>A | p.Arg771Gln | p.R771Q | O15085 | protein_coding | deleterious(0.02) | benign(0.057) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ARHGEF11 | SNV | Missense_Mutation | c.2689N>G | p.Met897Val | p.M897V | O15085 | protein_coding | tolerated(0.11) | benign(0.069) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGEF11 | SNV | Missense_Mutation | rs761370827 | c.2863N>A | p.Glu955Lys | p.E955K | O15085 | protein_coding | tolerated(0.46) | benign(0.089) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |